MDxHealth S.A.

NASDAQ:MDXH

Medical - Diagnostics & Research

Healthcare
$0.60 -4.45%

-$0.03 today

Market cap
$57.59M
Beta
0.38
P/E (TTM)
-1.0
EPS (TTM)
-$0.58
52W Low $0.40High $5.33

Volume 0.65M

Average 4.27M

MDXH Gross Margin

Gross profit as a percentage of revenue, showing how much of each sales dollar is kept after direct costs.

MDxHealth S.A.NASDAQ: MDXH

Gross Margin · Q2 FY2026 · quarter ended Jun 2026

Gross margin holds steady near 65.7%

Gross margin was 65.7% in Q2 FY2026, down 0.3 pp from a year earlier. Over 3 fiscal years it widened by 7.9 pp.

Context

  • Gross margin widened in 1 of the last 3 fiscal years.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
65.7%— QoQ
Last fiscal yearDec 2025
59.7%-1.5 pp YoY
Gross Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter-0.3 pp——
1 year-1.5 pp——
3 years+7.9 pp——
5 years——
10 years——

Gross Margin history

Percent of revenue · from the income statement

Latest · FY2025
59.7%
Year-over-year change
-1.5pp

Gross Margin vs competitors

How MDXH compares with its peers on the latest reported figures

  • MDXH's FY2025 gross margin of 59.7% is the 5th highest of the 9 companies compared; the peer median is 66.9%.
  • Its year-over-year change of -1.5 pp is the 8th highest of 9, against a peer median of -0.3 pp.
  • Over three fiscal years its change of +7.9 pp compares with a peer median of +3.3 pp.
MDXH Competitors Peer median
Gross Margin for MDXH and competitors
Company Period LTM level YoY 3-year change
ASMBAssembly Biosciences, Inc.LTM Mar 202677.2% +110.0 pp—
ACRSAclaris Therapeutics, Inc.LTM Mar 202676.3% +55.8 pp+13.5 pp
SNWVSANUWAVE Health, Inc.LTM Mar 202675.7% -0.9 pp+3.0 pp
SIShoulder Innovations, Inc.LTM Mar 202675.5% +0.4 pp—
MDXHMDxHealth S.A.FY202559.7% -1.5 pp+7.9 pp
XGNExagen Inc.LTM Mar 202658.3% -1.0 pp+11.4 pp
STXSStereotaxis, Inc.LTM Mar 202653.9% +0.5 pp-12.9 pp
QTRXQuanterix CorporationLTM Mar 202644.1% -15.0 pp+3.7 pp
NEONeoGenomics, Inc.LTM Jun 202642.9% -1.0 pp+2.0 pp
ZURAZura Bio LimitedFY2025— ——
IMRXImmuneering CorporationFY2025— ——
Peer median (excluding MDXH) 66.9%-0.3 pp+3.3 pp

Competitors are the stored peer set for MDXH. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue22.24M37.05M70.19M90.05M107.88M
Cost of Revenue11.68M17.84M26.26M34.91M43.43M
Gross Profit10.56M19.22M43.93M55.14M64.44M
Gross Margin47.5%51.9%62.6%61.2%59.7%
Research & Development5.59M7.56M6.38M10.55M10.35M
Selling, General & Admin30.22M50.12M59.93M61.4M66.75M
Operating Expenses37.41M57.12M71.26M79.86M79.84M
Depreciation & Amortization3.04M4.91M6.86M8.04M9.21M
EBITDA(24.09M)(36.39M)(30.47M)(22.02M)(14.01M)
EBITDA Margin-108.3%-98.2%-43.4%-24.5%-13.0%
Operating Income(26.84M)(37.9M)(27.33M)(24.72M)(15.4M)
Operating Margin-120.7%-102.3%-38.9%-27.5%-14.3%
Interest Income11K125K1.09M1.08M1.5M
Interest Expense1.88M2.74M5.77M7.63M12.16M
Other Income / Expenses(2.16M)(6.14M)(15.77M)(12.97M)(19.98M)
Income Before Tax(29M)(44.04M)(43.1M)(37.69M)(35.38M)
Pre-Tax Margin-130.4%-118.9%-61.4%-41.9%-32.8%
Income Tax Expense001K382K(1.86M)
Net Income(29M)(44.04M)(43.1M)(38.07M)(33.52M)
Net Margin-130.4%-118.9%-61.4%-42.3%-31.1%
EPS (Basic)(2.38)(2.78)(1.66)(0.78)(0.67)
EPS (Diluted)(2.38)(2.78)(1.66)(1.16)(0.67)
Weighted Avg Shares12.19M15.87M25.91M48.67M50.03M
Weighted Avg Shares (Diluted)12.19M15.87M25.91M48.67M50.03M

MDxHealth S.A.

NASDAQ:MDXH

Intrinsic Alpha fair value

Locked

Current Price

$0.60

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.